<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604526</url>
  </required_header>
  <id_info>
    <org_study_id>06-122</org_study_id>
    <nct_id>NCT00604526</nct_id>
  </id_info>
  <brief_title>High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy</brief_title>
  <official_title>Pilot Study of High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      High dose rate (HDR) brachytherapy is a form of radiation treatment using temporary&#xD;
      radioactive seeds. This is done by placing very tiny catheters or tubes into the prostate and&#xD;
      then inserting temporary radioactive seeds, called Iridium 192, through these catheters. HDR&#xD;
      brachytherapy gives precise radiation to the prostate with less radiation given to the normal&#xD;
      tissues near the prostate. For patients who have been treated with external beam radiation to&#xD;
      the prostate before, HDR brachytherapy can give radiation again to the prostate without&#xD;
      exposing the normal tissues around the prostate to significantly more radiation. This may be&#xD;
      safer than giving external beam radiation again. The purpose of this study is to test the&#xD;
      safety of high dose rate temporary brachytherapy (HDR) for prostate cancer that has come back&#xD;
      after external beam radiation. We want to find out what effects, good and/or bad, the&#xD;
      treatment has on you and your recurrent prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assess feasibility &amp; toxicity of HDR as salvage ther for local recurrent prostate cancer after ext beam radiotherapy. QOL instruments and questionnaires including the MSK prostate QOL instrument, the IIEF, IPSS , &amp; the NCI CTC is used to assess toxicity.</measure>
    <time_frame>conclusion of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess biochemical or PSA relapse free survival.</measure>
    <time_frame>conclusion of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Questionnaires, Iridium 192 radioactive seeds</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds</intervention_name>
    <description>Pre-tx Sexual function questionnaire Quality of Life baseline, Treatment with HDR (Two days) Treatment: Iridium 192 radioactive seeds temporarily inserted into patient. Post treatment (after HDR) Month 1 (+/- 2 weeks), 3 (+/- 1 month), 6 (+/- 1 month), 9 (+/-1 month), 12 (+/- 1 month)* NCI CTC GU and GI assessment,IPSS, IIEF, PSA lab test, Prostate HRQOL&#xD;
*After 1 year, will follow up with doctor about every 6 months.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  KPS &gt; than or equal to 80&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Able to complete toxicity scales and questionnaires&#xD;
&#xD;
          -  Histologically MSKCC confirmed diagnosis of recurrent prostate cancer.&#xD;
&#xD;
          -  Documented history of definitive radiotherapy to the prostate gland&#xD;
&#xD;
          -  IPSS of &lt; than or equal to 15 at the time of evaluation&#xD;
&#xD;
          -  PSA &lt; than or equal to 15 ng/ml&#xD;
&#xD;
          -  Organ confined disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to tolerate general anesthesia&#xD;
&#xD;
          -  Abnormal complete blood count. Any of the following:&#xD;
&#xD;
          -  Platelet count less than 75,000/ml&#xD;
&#xD;
          -  Hb level less than 10 gm/dl&#xD;
&#xD;
          -  WBC less than 3.5/ml&#xD;
&#xD;
          -  Abnormal coagulation profile:&#xD;
&#xD;
          -  INR &gt; 2.5&#xD;
&#xD;
          -  Abnormal Liver function tests (&gt;1.5 x normal value)&#xD;
&#xD;
          -  Abnormal renal function tests (creatinine &gt; 1.5)&#xD;
&#xD;
          -  Evidence of metastatic disease (bone scan, radiographs, MRI findings)&#xD;
&#xD;
          -  Prostate volume &gt; 50 cc&#xD;
&#xD;
          -  Unable to meet treatment planning criteria&#xD;
&#xD;
          -  History of rectal surgery&#xD;
&#xD;
          -  External beam radiation dose to the prostate &gt; 86.4 Gy if standard treatment planning&#xD;
             dose constraints were met&#xD;
&#xD;
          -  History of inflammatory bowel disease&#xD;
&#xD;
          -  Expected survival &lt; 1 year&#xD;
&#xD;
          -  Unable to undergo bone scan, CT or MRI evaluation&#xD;
&#xD;
          -  Unavailable for regular follow up&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshiya Yamada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

